OCGN
Ocugen, Inc.
Price Chart
Latest Quote
$1.36
-0.01 (-0.73%)
Current Price
| Previous Close | $1.37 |
| Open | $1.34 |
| Day High | $1.38 |
| Day Low | $1.34 |
| Volume | 3,758,514 |
Stock Information
| Shares Outstanding | 338.52M |
| Total Debt | $33.30M |
| Cash Equivalents | $31.86M |
| Revenue | $4.46M |
| Net Income | $-71.67M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $460.39M |
| EPS (TTM) | $-0.24 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $465.22M |
| Sales | $4.46M |
| Income | $-71.67M |
| Book/sh | $0.02 |
| Cash/sh | $0.09 |
| Employees | 116 |
Financial Ratios
| Quick Ratio | 1.54 |
| Current Ratio | 1.86 |
| Debt/Eq | 573.58 |
Returns & Margins
| ROA | -68.24% |
| ROE | -660.00% |
| Operating Margin | -1163.67% |
Ownership
| Insider Ownership | 1.68% |
| Institutional Ownership | 34.57% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.79 |
| P/S | 103.11 |
| P/B | 80.00 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $11.43 |
Technical Indicators
| SMA20 | $1.44 |
| SMA50 | $1.38 |
| SMA200 | $1.55 |
| RSI | 38.33 |
| ATR | 0.0907 |
| Shares Float | 316.84M |
| Short Float | 31.31% |
| Short Ratio | 10.98 |
| Volatility | 2.18 |
| Rel Volume | 0.38 |
Performance History
| Week | -7.48% |
| Month | +15.25% |
| Quarter | -29.53% |
| 6 Months | -27.66% |
| YTD | -1.45% |
| Year | +30.77% |
| 3 Years | +127.05% |
| 5 Years | -81.29% |
| 10 Years | -98.79% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $1.36 | 3,758,514 |
| 2026-07-16 | $1.37 | 5,003,400 |
| 2026-07-15 | $1.43 | 3,577,100 |
| 2026-07-14 | $1.43 | 4,964,400 |
| 2026-07-13 | $1.41 | 5,548,400 |
| 2026-07-10 | $1.47 | 3,513,300 |
| 2026-07-09 | $1.47 | 5,466,000 |
| 2026-07-08 | $1.50 | 7,570,700 |
| 2026-07-07 | $1.50 | 4,758,900 |
| 2026-07-06 | $1.49 | 5,463,000 |
| 2026-07-02 | $1.51 | 6,953,200 |
| 2026-07-01 | $1.48 | 5,810,200 |
| 2026-06-30 | $1.53 | 11,445,600 |
| 2026-06-29 | $1.67 | 14,239,000 |
| 2026-06-26 | $1.50 | 57,047,100 |
| 2026-06-25 | $1.37 | 5,749,700 |
| 2026-06-24 | $1.39 | 6,545,600 |
| 2026-06-23 | $1.38 | 8,225,000 |
| 2026-06-22 | $1.29 | 6,219,400 |
| 2026-06-18 | $1.24 | 26,269,800 |
About Ocugen, Inc.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
đ° Latest News
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances
MarketBeat âĸ 2026-07-11T00:02:06Z
Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst View
Simply Wall St. âĸ 2026-06-25T00:23:01Z
How The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst Guidance
Simply Wall St. âĸ 2026-06-06T01:05:37Z
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
Zacks âĸ 2026-06-04T15:30:23Z
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
Zacks âĸ 2026-06-03T15:50:00Z
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?
Zacks âĸ 2026-06-03T15:39:00Z
OCGN's Catalyst Calendar for Trial Data and Filings Through 2028
Zacks âĸ 2026-06-03T15:35:00Z
Ocugen (OCGN) Reports Q1 EPS
Insider Monkey âĸ 2026-05-13T06:21:09Z
Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed?
Simply Wall St. âĸ 2026-05-09T00:28:18Z
Ocugen (OCGN) Upgraded to Buy: Here's Why
Zacks âĸ 2026-05-08T16:00:06Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $4,413,000 | $4,055,000 | $6,036,000 | $2,488,000 |
| Operating Revenue | $4,413,000 | $4,055,000 | $6,036,000 | $2,488,000 |
| Expenses | ||||
| Interest Expense | $5,188,000 | $688,000 | - | - |
| Total Expenses | $67,329,000 | $58,812,000 | $71,567,000 | $91,559,000 |
| Other Income Expense | $-664,000 | $140,000 | $2,453,000 | $2,267,000 |
| Other Non Operating Income Expenses | $-664,000 | $140,000 | $2,453,000 | $2,267,000 |
| Net Non Operating Interest Income Expense | $-4,266,000 | $563,000 | - | - |
| Interest Expense Non Operating | $5,188,000 | $688,000 | - | - |
| Operating Expense | $67,329,000 | $58,812,000 | $71,567,000 | $91,559,000 |
| General And Administrative Expense | $27,579,000 | $26,686,000 | $31,994,000 | $35,400,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-67,846,000 | $-54,054,000 | $-63,078,000 | $-86,804,000 |
| Net Interest Income | $-4,266,000 | $563,000 | - | - |
| Interest Income | $922,000 | $1,251,000 | - | - |
| Normalized Income | $-67,846,000 | $-54,054,000 | $-63,078,000 | $-86,804,000 |
| Net Income From Continuing And Discontinued Operation | $-67,846,000 | $-54,054,000 | $-63,078,000 | $-86,804,000 |
| Total Operating Income As Reported | $-62,916,000 | $-54,757,000 | $-65,531,000 | $-89,071,000 |
| Net Income Common Stockholders | $-67,846,000 | $-54,054,000 | $-63,078,000 | $-86,804,000 |
| Net Income | $-67,846,000 | $-54,054,000 | $-63,078,000 | $-86,804,000 |
| Net Income Including Noncontrolling Interests | $-67,846,000 | $-54,054,000 | $-63,078,000 | $-86,804,000 |
| Net Income Continuous Operations | $-67,846,000 | $-54,054,000 | $-63,078,000 | $-86,804,000 |
| Pretax Income | $-67,846,000 | $-54,054,000 | $-63,078,000 | $-86,804,000 |
| Interest Income Non Operating | $922,000 | $1,251,000 | - | - |
| Operating Income | $-62,916,000 | $-54,757,000 | $-65,531,000 | $-89,071,000 |
| Special Income Charges | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.23 | $-0.20 | $-0.26 | $-0.38 |
| Basic EPS | $-0.23 | $-0.20 | $-0.26 | $-0.38 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-60,269,000 | $-51,398,000 | $-64,827,000 | $-88,591,000 |
| Reconciled Depreciation | $2,389,000 | $1,968,000 | $704,000 | $480,000 |
| EBITDA (Bullshit earnings) | $-60,269,000 | $-51,398,000 | $-64,827,000 | $-88,591,000 |
| EBIT | $-62,658,000 | $-53,366,000 | $-65,531,000 | $-89,071,000 |
| Diluted Average Shares | $300,167,989 | $270,995,121 | $244,327,057 | $214,600,051 |
| Basic Average Shares | $300,167,989 | $270,995,121 | $244,327,057 | $214,600,051 |
| Diluted NI Availto Com Stockholders | $-67,846,000 | $-54,054,000 | $-63,078,000 | $-86,804,000 |
| Research And Development | $39,750,000 | $32,126,000 | $39,573,000 | $56,159,000 |
| Selling General And Administration | $27,579,000 | $26,686,000 | $31,994,000 | $35,400,000 |
| Other Gand A | $27,579,000 | $26,686,000 | $31,994,000 | $35,400,000 |
| Tax Provision | - | - | - | $0 |
| Total Unusual Items | - | - | - | - |
| Total Unusual Items Excluding Goodwill | - | - | - | - |
Fetched: 2026-07-10
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-12,166,000 | $29,632,000 | $40,564,000 | $73,981,000 |
| Total Assets | $43,516,000 | $82,442,000 | $64,547,000 | $108,632,000 |
| Total Non Current Assets | $19,176,000 | $20,760,000 | $21,576,000 | $10,140,000 |
| Other Non Current Assets | $4,784,000 | $4,206,000 | $4,286,000 | $4,087,000 |
| Current Assets | $24,340,000 | $61,682,000 | $42,971,000 | $98,492,000 |
| Other Current Assets | $5,769,000 | $3,168,000 | $3,509,000 | $7,558,000 |
| Cash Cash Equivalents And Short Term Investments | $18,571,000 | $58,514,000 | $39,462,000 | $90,934,000 |
| Cash And Cash Equivalents | $18,571,000 | $58,514,000 | $39,462,000 | $77,563,000 |
| Cash Financial | $18,571,000 | $58,514,000 | $39,462,000 | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $10,221,000 | - | - | - |
| Total Debt | $33,144,000 | $32,503,000 | $6,941,000 | $6,374,000 |
| Long Term Debt And Capital Lease Obligation | $31,036,000 | $30,658,000 | $6,367,000 | $5,876,000 |
| Long Term Debt | $27,542,000 | $27,345,000 | $2,800,000 | $2,289,000 |
| Current Debt And Capital Lease Obligation | $2,108,000 | $1,845,000 | $574,000 | $498,000 |
| Current Debt | $1,250,000 | $1,326,000 | - | - |
| Other Current Borrowings | $1,250,000 | $1,326,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $55,682,000 | $52,810,000 | $23,983,000 | $34,651,000 |
| Total Non Current Liabilities Net Minority Interest | $32,639,000 | $31,222,000 | $6,894,000 | $6,120,000 |
| Other Non Current Liabilities | $1,603,000 | $564,000 | $527,000 | $244,000 |
| Current Liabilities | $23,043,000 | $21,588,000 | $17,089,000 | $28,531,000 |
| Other Current Liabilities | $3,386,000 | $2,822,000 | $151,000 | $357,000 |
| Current Deferred Liabilities | $5,907,000 | $8,368,000 | $10,525,000 | $11,221,000 |
| Payables And Accrued Expenses | $8,340,000 | $6,120,000 | $4,048,000 | $13,703,000 |
| Payables | $6,202,000 | $4,243,000 | $3,172,000 | $8,062,000 |
| Accounts Payable | $6,202,000 | $4,243,000 | $3,172,000 | $8,062,000 |
| Equity | ||||
| Common Stock Equity | $-12,166,000 | $29,632,000 | $40,563,000 | $73,980,000 |
| Total Equity Gross Minority Interest | $-12,166,000 | $29,632,000 | $40,564,000 | $73,981,000 |
| Stockholders Equity | $-12,166,000 | $29,632,000 | $40,564,000 | $73,981,000 |
| Gains Losses Not Affecting Retained Earnings | $61,000 | $48,000 | $20,000 | $26,000 |
| Other Equity Adjustments | $61,000 | $48,000 | $20,000 | $26,000 |
| Retained Earnings | $-408,067,000 | $-340,221,000 | $-286,167,000 | $-223,089,000 |
| Preferred Stock Equity | - | - | $1,000 | $1,000 |
| Other | ||||
| Treasury Shares Number | $121,500 | $121,500 | $121,500 | $121,500 |
| Ordinary Shares Number | $312,379,972 | $291,367,558 | $256,566,804 | $221,599,682 |
| Share Issued | $312,501,472 | $291,489,058 | $256,688,304 | $221,721,182 |
| Tangible Book Value | $-12,166,000 | $29,632,000 | $40,563,000 | $73,980,000 |
| Invested Capital | $16,626,000 | $58,303,000 | $43,363,000 | $76,269,000 |
| Working Capital | $1,297,000 | $40,094,000 | $25,882,000 | $69,961,000 |
| Capital Lease Obligations | $4,352,000 | $3,832,000 | $4,141,000 | $4,085,000 |
| Total Capitalization | $15,376,000 | $56,977,000 | $43,364,000 | $76,270,000 |
| Treasury Stock | $48,000 | $48,000 | $48,000 | $48,000 |
| Additional Paid In Capital | $392,763,000 | $366,938,000 | $324,191,000 | $294,874,000 |
| Capital Stock | $3,125,000 | $2,915,000 | $2,568,000 | $2,218,000 |
| Common Stock | $3,125,000 | $2,915,000 | $2,567,000 | $2,217,000 |
| Preferred Stock | $0 | $0 | $1,000 | $1,000 |
| Long Term Capital Lease Obligation | $3,494,000 | $3,313,000 | $3,567,000 | $3,587,000 |
| Current Deferred Revenue | $5,907,000 | $8,368,000 | $10,525,000 | $11,221,000 |
| Current Capital Lease Obligation | $858,000 | $519,000 | $574,000 | $498,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,302,000 | $2,433,000 | $1,791,000 | $2,752,000 |
| Current Accrued Expenses | $2,138,000 | $1,877,000 | $876,000 | $5,641,000 |
| Net PPE | $14,392,000 | $16,554,000 | $17,290,000 | $6,053,000 |
| Accumulated Depreciation | $-5,513,000 | $-3,160,000 | $-1,230,000 | $-621,000 |
| Gross PPE | $19,905,000 | $19,714,000 | $18,520,000 | $6,674,000 |
| Leases | $16,089,000 | $16,089,000 | $2,086,000 | $1,603,000 |
| Machinery Furniture Equipment | $3,816,000 | $3,625,000 | $1,894,000 | $2,022,000 |
| Properties | $0 | $0 | $0 | $0 |
| Construction In Progress | - | $0 | $14,540,000 | $3,049,000 |
| Other Short Term Investments | - | - | $0 | $13,371,000 |
Fetched: 2026-07-10
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-57,149,000 | $-45,527,000 | $-72,530,000 | $-64,536,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-56,964,000 | $-42,142,000 | $-62,054,000 | $-60,079,000 |
| Cash Flow From Continuing Operating Activities | $-56,964,000 | $-42,142,000 | $-62,054,000 | $-60,079,000 |
| Operating Gains Losses | - | - | $363,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-185,000 | $-3,385,000 | $-10,476,000 | $-4,457,000 |
| Investing Cash Flow | $-311,000 | $-3,385,000 | $3,077,000 | $-16,967,000 |
| Cash Flow From Continuing Investing Activities | $-311,000 | $-3,385,000 | $3,077,000 | $-16,967,000 |
| Net Other Investing Changes | - | - | - | $761,000 |
| Financing Activities | ||||
| Financing Cash Flow | $17,328,000 | $64,858,000 | $20,881,000 | $59,475,000 |
| Cash Flow From Continuing Financing Activities | $17,328,000 | $64,858,000 | $20,881,000 | $59,475,000 |
| Net Other Financing Charges | $-1,526,000 | $-3,698,000 | $-423,000 | $-592,000 |
| Net Common Stock Issuance | $19,854,000 | $38,556,000 | $20,804,000 | $59,567,000 |
| Issuance Of Capital Stock | - | - | $20,804,000 | $59,567,000 |
| Common Stock Issuance | - | - | $20,804,000 | $59,567,000 |
| Repurchase Of Capital Stock | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-1,000,000 | $0 | - | $0 |
| Issuance Of Debt | $0 | $30,000,000 | $500,000 | $500,000 |
| End Cash Position | $18,887,000 | $58,821,000 | $39,462,000 | $77,563,000 |
| Beginning Cash Position | $58,821,000 | $39,462,000 | $77,563,000 | $95,109,000 |
| Effect Of Exchange Rate Changes | $13,000 | $28,000 | $-5,000 | $25,000 |
| Changes In Cash | $-39,947,000 | $19,331,000 | $-38,096,000 | $-17,571,000 |
| Net Issuance Payments Of Debt | $-1,000,000 | $30,000,000 | $500,000 | $500,000 |
| Net Long Term Debt Issuance | $-1,000,000 | $30,000,000 | $500,000 | $500,000 |
| Long Term Debt Payments | $-1,000,000 | $0 | - | $0 |
| Long Term Debt Issuance | $0 | $30,000,000 | $500,000 | $500,000 |
| Net Investment Purchase And Sale | $-126,000 | $0 | $13,553,000 | $-13,271,000 |
| Purchase Of Investment | $-126,000 | $0 | $-3,947,000 | $-13,271,000 |
| Net PPE Purchase And Sale | $-185,000 | $-3,385,000 | $-10,476,000 | $-4,457,000 |
| Purchase Of PPE | $-185,000 | $-3,385,000 | $-10,476,000 | $-4,457,000 |
| Change In Working Capital | $-523,000 | $3,665,000 | $-13,156,000 | $9,195,000 |
| Change In Other Current Liabilities | $-1,227,000 | $-833,000 | $-517,000 | $-383,000 |
| Change In Payables And Accrued Expense | $3,311,000 | $4,137,000 | $-12,343,000 | $9,487,000 |
| Change In Prepaid Assets | $-2,607,000 | $361,000 | $-296,000 | $91,000 |
| Other Non Cash Items | $1,309,000 | $-1,148,000 | $4,000 | $6,608,000 |
| Stock Based Compensation | $7,707,000 | $7,427,000 | $9,217,000 | $10,541,000 |
| Depreciation Amortization Depletion | $2,389,000 | $1,968,000 | $704,000 | $480,000 |
| Depreciation And Amortization | $2,389,000 | $1,968,000 | $704,000 | $480,000 |
| Net Income From Continuing Operations | $-67,846,000 | $-54,054,000 | $-63,078,000 | $-86,804,000 |
| Sale Of Investment | - | $0 | $17,500,000 | $0 |
| Asset Impairment Charge | - | $0 | $4,074,000 | $0 |
| Amortization Of Securities | - | $0 | $-182,000 | $-99,000 |
| Gain Loss On Sale Of PPE | - | $0 | $363,000 | $0 |
| Change In Other Current Assets | - | - | - | $0 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
| Common Stock Payments | - | - | - | - |
Fetched: 2026-07-10